<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20231104060732&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20231104060732&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 04 Nov 2023 10:07:34 +0000</lastbuilddate>
<pubDate>Fri, 03 Nov 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37921497/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 27;133(10):789. doi: 10.1161/RES.0000000000000640. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37921497/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37921497</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000640>10.1161/RES.0000000000000640</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37921497</guid>
<pubDate>Fri, 03 Nov 2023 06:00:00 -0400</pubDate>
<dc:date>2023-11-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:37921497</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000640</dc:identifier>
</item>
<item>
<title>Prevention of atrial fibrillation: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37919240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 31:ehad738. doi: 10.1093/eurheartj/ehad738. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37919240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37919240</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad738>10.1093/eurheartj/ehad738</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37919240</guid>
<pubDate>Thu, 02 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Adrian D Elliott</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Melissa E Middeldorp</dc:creator>
<dc:date>2023-11-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prevention of atrial fibrillation: a call to action</dc:title>
<dc:identifier>pmid:37919240</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad738</dc:identifier>
</item>
<item>
<title>The proteomic landscape of synaptic diversity across brain regions and cell types</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37918396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>Neurons build synaptic contacts using different protein combinations that define the specificity, function, and plasticity potential of synapses; however, the diversity of synaptic proteomes remains largely unexplored. We prepared synaptosomes from 7 different transgenic mouse lines with fluorescently labeled presynaptic terminals. Combining microdissection of 5 different brain regions with fluorescent-activated synaptosome sorting (FASS), we isolated and analyzed the proteomes of 18 different...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 26:S0092-8674(23)01082-6. doi: 10.1016/j.cell.2023.09.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Neurons build synaptic contacts using different protein combinations that define the specificity, function, and plasticity potential of synapses; however, the diversity of synaptic proteomes remains largely unexplored. We prepared synaptosomes from 7 different transgenic mouse lines with fluorescently labeled presynaptic terminals. Combining microdissection of 5 different brain regions with fluorescent-activated synaptosome sorting (FASS), we isolated and analyzed the proteomes of 18 different synapse types. We discovered ∼1,800 unique synapse-type-enriched proteins and allocated thousands of proteins to different types of synapses (https://syndive.org/). We identify shared synaptic protein modules and highlight the proteomic hotspots for synapse specialization. We reveal unique and common features of the striatal dopaminergic proteome and discover the proteome signatures that relate to the functional properties of different interneuron classes. This study provides a molecular systems-biology analysis of synapses and a framework to integrate proteomic information for synapse subtypes of interest with cellular or circuit-level experiments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37918396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37918396</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.028>10.1016/j.cell.2023.09.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37918396</guid>
<pubDate>Thu, 02 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Marc van Oostrum</dc:creator>
<dc:creator>Thomas M Blok</dc:creator>
<dc:creator>Stefano L Giandomenico</dc:creator>
<dc:creator>Susanne Tom Dieck</dc:creator>
<dc:creator>Georgi Tushev</dc:creator>
<dc:creator>Nicole Fürst</dc:creator>
<dc:creator>Julian D Langer</dc:creator>
<dc:creator>Erin M Schuman</dc:creator>
<dc:date>2023-11-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The proteomic landscape of synaptic diversity across brain regions and cell types</dc:title>
<dc:identifier>pmid:37918396</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.028</dc:identifier>
</item>
<item>
<title>Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37918395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the virulence-associated type III secretion system (T3SS) in a cohort of patients chronically infected with PA. Single-cell analytics revealed a diverse B cell receptor repertoire directed against the T3SS needle-tip protein PcrV, enabling the production of monoclonal antibodies (mAbs) abrogating...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 27:S0092-8674(23)01084-X. doi: 10.1016/j.cell.2023.10.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the virulence-associated type III secretion system (T3SS) in a cohort of patients chronically infected with PA. Single-cell analytics revealed a diverse B cell receptor repertoire directed against the T3SS needle-tip protein PcrV, enabling the production of monoclonal antibodies (mAbs) abrogating T3SS-mediated cytotoxicity. Mechanistic studies involving cryoelectron microscopy identified a surface-exposed C-terminal PcrV epitope as the target of highly neutralizing mAbs with broad activity against drug-resistant PA isolates. These anti-PcrV mAbs were as effective as treatment with conventional antibiotics in vivo. Our study reveals that chronically infected patients represent a source of neutralizing antibodies, which can be exploited as therapeutics against PA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37918395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37918395</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.002>10.1016/j.cell.2023.10.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37918395</guid>
<pubDate>Thu, 02 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexander Simonis</dc:creator>
<dc:creator>Christoph Kreer</dc:creator>
<dc:creator>Alexandra Albus</dc:creator>
<dc:creator>Katharina Rox</dc:creator>
<dc:creator>Biao Yuan</dc:creator>
<dc:creator>Dmitriy Holzmann</dc:creator>
<dc:creator>Joana A Wilms</dc:creator>
<dc:creator>Sylvia Zuber</dc:creator>
<dc:creator>Lisa Kottege</dc:creator>
<dc:creator>Sandra Winter</dc:creator>
<dc:creator>Meike Meyer</dc:creator>
<dc:creator>Kristin Schmitt</dc:creator>
<dc:creator>Henning Gruell</dc:creator>
<dc:creator>Sebastian J Theobald</dc:creator>
<dc:creator>Anna-Maria Hellmann</dc:creator>
<dc:creator>Christina Meyer</dc:creator>
<dc:creator>Meryem Seda Ercanoglu</dc:creator>
<dc:creator>Nina Cramer</dc:creator>
<dc:creator>Antje Munder</dc:creator>
<dc:creator>Michael Hallek</dc:creator>
<dc:creator>Gerd Fätkenheuer</dc:creator>
<dc:creator>Manuel Koch</dc:creator>
<dc:creator>Harald Seifert</dc:creator>
<dc:creator>Ernst Rietschel</dc:creator>
<dc:creator>Thomas C Marlovits</dc:creator>
<dc:creator>Silke van Koningsbruggen-Rietschel</dc:creator>
<dc:creator>Florian Klein</dc:creator>
<dc:creator>Jan Rybniker</dc:creator>
<dc:date>2023-11-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa</dc:title>
<dc:identifier>pmid:37918395</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.002</dc:identifier>
</item>
<item>
<title>Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37918394/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 26:S0092-8674(23)01083-8. doi: 10.1016/j.cell.2023.10.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to intracellular 4-1BB/CD3ζ domains. NMDAR-CAAR T cells recognize a large panel of human patient-derived autoantibodies, release effector molecules, proliferate, and selectively kill antigen-specific target cell lines even in the presence of high autoantibody concentrations. In a passive transfer mouse model, NMDAR-CAAR T cells led to depletion of an anti-NMDAR B cell line and sustained reduction of autoantibody levels without notable off-target toxicity. Treatment of patients may reduce side effects, prevent relapses, and improve long-term prognosis. Our preclinical work paves the way for CAAR T cell phase I/II trials in NMDAR encephalitis and further autoantibody-mediated diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37918394/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37918394</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.001>10.1016/j.cell.2023.10.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37918394</guid>
<pubDate>Thu, 02 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>S Momsen Reincke</dc:creator>
<dc:creator>Niels von Wardenburg</dc:creator>
<dc:creator>Marie A Homeyer</dc:creator>
<dc:creator>Hans-Christian Kornau</dc:creator>
<dc:creator>Gregorio Spagni</dc:creator>
<dc:creator>Lucie Y Li</dc:creator>
<dc:creator>Jakob Kreye</dc:creator>
<dc:creator>Elisa Sánchez-Sendín</dc:creator>
<dc:creator>Sonja Blumenau</dc:creator>
<dc:creator>Dominik Stappert</dc:creator>
<dc:creator>Helena Radbruch</dc:creator>
<dc:creator>Anja E Hauser</dc:creator>
<dc:creator>Annette Künkele</dc:creator>
<dc:creator>Inan Edes</dc:creator>
<dc:creator>Dietmar Schmitz</dc:creator>
<dc:creator>Harald Prüss</dc:creator>
<dc:date>2023-11-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells</dc:title>
<dc:identifier>pmid:37918394</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.001</dc:identifier>
</item>
<item>
<title>2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>Rheumatic heart disease (RHD) is an important and preventable cause of morbidity and mortality among children and young adults in low-income and middle-income countries, as well as among certain at-risk populations living in high-income countries. The 2012 World Heart Federation echocardiographic criteria provided a standardized approach for the identification of RHD and facilitated an improvement in early case detection. The 2012 criteria were used to define disease burden in numerous...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 2. doi: 10.1038/s41569-023-00940-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Rheumatic heart disease (RHD) is an important and preventable cause of morbidity and mortality among children and young adults in low-income and middle-income countries, as well as among certain at-risk populations living in high-income countries. The 2012 World Heart Federation echocardiographic criteria provided a standardized approach for the identification of RHD and facilitated an improvement in early case detection. The 2012 criteria were used to define disease burden in numerous epidemiological studies, but researchers and clinicians have since highlighted limitations that have prompted a revision. In this updated version of the guidelines, we incorporate evidence from a scoping review, an expert panel and end-user feedback and present an approach for active case finding for RHD, including the use of screening and confirmatory criteria. These guidelines also introduce a new stage-based classification for RHD to identify the risk of disease progression. They describe the latest evidence and recommendations on population-based echocardiographic active case finding and risk stratification. Secondary antibiotic prophylaxis, echocardiography equipment and task sharing for RHD active case finding are also discussed. These World Heart Federation 2023 guidelines provide a concise and updated resource for clinical and research applications in RHD-endemic regions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914787</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00940-9>10.1038/s41569-023-00940-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914787</guid>
<pubDate>Thu, 02 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Joselyn Rwebembera</dc:creator>
<dc:creator>James Marangou</dc:creator>
<dc:creator>Julius Chacha Mwita</dc:creator>
<dc:creator>Ana Olga Mocumbi</dc:creator>
<dc:creator>Cleonice Mota</dc:creator>
<dc:creator>Emmy Okello</dc:creator>
<dc:creator>Bruno Nascimento</dc:creator>
<dc:creator>Lene Thorup</dc:creator>
<dc:creator>Andrea Beaton</dc:creator>
<dc:creator>Joseph Kado</dc:creator>
<dc:creator>Alexander Kaethner</dc:creator>
<dc:creator>Raman Krishna Kumar</dc:creator>
<dc:creator>John Lawrenson</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Mariana Mirabel</dc:creator>
<dc:creator>Maria Carmo Pereira Nunes</dc:creator>
<dc:creator>Daniel Piñeiro</dc:creator>
<dc:creator>Fausto Pinto</dc:creator>
<dc:creator>Kate Ralston</dc:creator>
<dc:creator>Craig Sable</dc:creator>
<dc:creator>Amy Sanyahumbi</dc:creator>
<dc:creator>Anita Saxena</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Andrew Steer</dc:creator>
<dc:creator>Satupaitea Viali</dc:creator>
<dc:creator>Gavin Wheaton</dc:creator>
<dc:creator>Nigel Wilson</dc:creator>
<dc:creator>Liesl Zühlke</dc:creator>
<dc:creator>Bo Reményi</dc:creator>
<dc:date>2023-11-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease</dc:title>
<dc:identifier>pmid:37914787</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00940-9</dc:identifier>
</item>
<item>
<title>Reply: Targeting Symptom Preoccupation in Atrial Fibrillation: A Promising Treatment Approach and Avenue for Future Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):e183-e184. doi: 10.1016/j.jacc.2023.08.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914521</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.047>10.1016/j.jacc.2023.08.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914521</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Josefin Särnholm</dc:creator>
<dc:creator>Brjánn Ljótsson</dc:creator>
<dc:creator>Frieder Braunschweig</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Targeting Symptom Preoccupation in Atrial Fibrillation: A Promising Treatment Approach and Avenue for Future Research</dc:title>
<dc:identifier>pmid:37914521</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.047</dc:identifier>
</item>
<item>
<title>Caution Warranted Regarding the Efficacy of iCBT in Patients With Symptomatic Paroxysmal Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):e181. doi: 10.1016/j.jacc.2023.07.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914520</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.035>10.1016/j.jacc.2023.07.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914520</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Peter Andersson</dc:creator>
<dc:creator>James Coyne</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Caution Warranted Regarding the Efficacy of iCBT in Patients With Symptomatic Paroxysmal Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37914520</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.035</dc:identifier>
</item>
<item>
<title>Postmenopausal Women With Atrial Fibrillation and Mental Health Symptoms: A Group Deserving Attention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):e179. doi: 10.1016/j.jacc.2023.07.037.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914519</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.037>10.1016/j.jacc.2023.07.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914519</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Jieyi Wang</dc:creator>
<dc:creator>Ruiting Jia</dc:creator>
<dc:creator>Yulin Lu</dc:creator>
<dc:creator>Wumin Yu</dc:creator>
<dc:creator>Aisong Zhu</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Postmenopausal Women With Atrial Fibrillation and Mental Health Symptoms: A Group Deserving Attention</dc:title>
<dc:identifier>pmid:37914519</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.037</dc:identifier>
</item>
<item>
<title>Beyond the Surface: Scrutinizing Methodological Biases in a Study on iCBT for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):e177. doi: 10.1016/j.jacc.2023.07.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914518</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.036>10.1016/j.jacc.2023.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914518</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Adrian E Desai Boström</dc:creator>
<dc:creator>Johan Lundberg</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Beyond the Surface: Scrutinizing Methodological Biases in a Study on iCBT for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37914518</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.036</dc:identifier>
</item>
<item>
<title>Cardiac Troponin Assays to Distinguish Between Acute and Chronic Myocardial Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1885-1887. doi: 10.1016/j.jacc.2023.08.048.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914517</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.048>10.1016/j.jacc.2023.08.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914517</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Nils A Sörensen</dc:creator>
<dc:creator>Linlin Guo</dc:creator>
<dc:creator>Paul M Haller</dc:creator>
<dc:creator>Farnaz Dehkordi</dc:creator>
<dc:creator>Jonas Lehmacher</dc:creator>
<dc:creator>Alina Schock</dc:creator>
<dc:creator>Betül Toprak</dc:creator>
<dc:creator>Tanja Zeller</dc:creator>
<dc:creator>Raphael Twerenbold</dc:creator>
<dc:creator>Johannes T Neumann</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Troponin Assays to Distinguish Between Acute and Chronic Myocardial Injury</dc:title>
<dc:identifier>pmid:37914517</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.048</dc:identifier>
</item>
<item>
<title>SGLT2i and Deterioration of Kidney Function in Heart Failure: Another Demonstration for Tolerance of "Hypercreatininemia"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1864-1867. doi: 10.1016/j.jacc.2023.09.797.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914516</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.797>10.1016/j.jacc.2023.09.797</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914516</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Steven G Coca</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>SGLT2i and Deterioration of Kidney Function in Heart Failure: Another Demonstration for Tolerance of "Hypercreatininemia"</dc:title>
<dc:identifier>pmid:37914516</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.797</dc:identifier>
</item>
<item>
<title>Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1852-1853. doi: 10.1016/j.jacc.2023.09.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914515</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.004>10.1016/j.jacc.2023.09.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914515</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Reza Mohebi</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level</dc:title>
<dc:identifier>pmid:37914515</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.004</dc:identifier>
</item>
<item>
<title>Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1842-1851. doi: 10.1016/j.jacc.2023.08.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trials demonstrated that sotagliflozin, an SGLT1 and SGLT2 inhibitor, improves outcomes in individuals with type 2 diabetes who have heart failure (HF) or kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We assessed the efficacy of sotagliflozin on HF clinical outcomes in individuals with differing baseline glycosylated hemoglobin (HbA1c) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included all adults from SCORED and SOLOIST-WHF. The primary outcome was a composite of cardiovascular death, hospitalizations for HF, and urgent visits for HF. The efficacy of sotagliflozin compared with placebo was evaluated by baseline HbA1c using competing-risk marginal proportional hazards models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 11,744 adults. Individuals with HbA1c ≤7.5% experienced the primary outcome at a lower rate in the sotagliflozin group (11.2 per 100 person-years) than the placebo group (15.5 per 100 person-years) (HR: 0.73; 95% CI: 0.57-0.93). Similarly, individuals with HbA1c of 7.6% to 9.0% experienced the primary outcome at a lower rate in the sotagliflozin group (7.3 per 100 person-years) than the placebo group (9.4 per 100 person-years) (HR: 0.77; 95% CI: 0.63-0.96). These findings were also consistent among individuals with HbA1c >;9.0%, with a primary outcome rate in the sotagliflozin group (7.8 per 100 person-years) that was lower than the placebo group (11.6 per 100 person-years) (HR: 0.65; 95% CI: 0.50-0.84). The efficacy of sotagliflozin was consistent by baseline HbA1c level (P for interaction = 0.58).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914514</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.050>10.1016/j.jacc.2023.08.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914514</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Rahul Aggarwal</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Christopher P Cannon</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Michael J Davies</dc:creator>
<dc:creator>Phillip Banks</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c</dc:title>
<dc:identifier>pmid:37914514</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.050</dc:identifier>
</item>
<item>
<title>Comparative Accuracy of Noninvasive Imaging Tests in Stable Chest Pain: Does It Matter?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1839-1841. doi: 10.1016/j.jacc.2023.09.805.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914513</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.805>10.1016/j.jacc.2023.09.805</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914513</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Sven Plein</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparative Accuracy of Noninvasive Imaging Tests in Stable Chest Pain: Does It Matter?</dc:title>
<dc:identifier>pmid:37914513</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.805</dc:identifier>
</item>
<item>
<title>Stress Perfusion Cardiac Magnetic Resonance vs SPECT Imaging for Detection of Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Vasodilator stress perfusion CMR, as performed with gadobutrol 0.1 mmol/kg body weight, had superior diagnostic accuracy for diagnosis and exclusion of significant CAD vs gated SPECT.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1828-1838. doi: 10.1016/j.jacc.2023.08.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: GadaCAD2 was 1 of 2 international, multicenter, prospective, Phase 3 clinical trials that led to U.S. Food and Drug Administration approval of gadobutrol to assess myocardial perfusion and late gadolinium enhancement (LGE) in adults with known or suspected coronary artery disease (CAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: A prespecified secondary objective was to determine if stress perfusion cardiovascular magnetic resonance (CMR) was noninferior to single-photon emission computed tomography (SPECT) for detecting significant CAD and for excluding significant CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants with known or suspected CAD underwent a research rest and stress perfusion CMR that was compared with a gated SPECT performed using standard clinical protocols. For CMR, adenosine or regadenoson served as vasodilators. The total dose of gadobutrol was 0.1 mmol/kg body weight. The standard of reference was a 70% stenosis defined by quantitative coronary angiography (QCA). A negative coronary computed tomography angiography could exclude CAD. Analysis was per patient. CMR, SPECT, and QCA were evaluated by independent central core lab readers blinded to clinical information.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Participants were predominantly male (61.4% male; mean age 58.9 ± 10.2 years) and were recruited from the United States (75.0%), Australia (14.7%), Singapore (5.7%), and Canada (4.6%). The prevalence of significant CAD was 24.5% (n = 72 of 294). Stress perfusion CMR was statistically superior to gated SPECT for specificity (P = 0.002), area under the receiver operating characteristic curve (P &lt; 0.001), accuracy (P = 0.003), positive predictive value (P &lt; 0.001), and negative predictive value (P = 0.041). The sensitivity of CMR for a 70% QCA stenosis was noninferior and nonsuperior to gated SPECT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vasodilator stress perfusion CMR, as performed with gadobutrol 0.1 mmol/kg body weight, had superior diagnostic accuracy for diagnosis and exclusion of significant CAD vs gated SPECT.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914512</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.046>10.1016/j.jacc.2023.08.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914512</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew E Arai</dc:creator>
<dc:creator>Jeanette Schulz-Menger</dc:creator>
<dc:creator>Dipan J Shah</dc:creator>
<dc:creator>Yuchi Han</dc:creator>
<dc:creator>W Patricia Bandettini</dc:creator>
<dc:creator>Arun Abraham</dc:creator>
<dc:creator>Pamela K Woodard</dc:creator>
<dc:creator>Joseph B Selvanayagam</dc:creator>
<dc:creator>Christian Hamilton-Craig</dc:creator>
<dc:creator>Ru-San Tan</dc:creator>
<dc:creator>James Carr</dc:creator>
<dc:creator>Lynette Teo</dc:creator>
<dc:creator>Christopher M Kramer</dc:creator>
<dc:creator>Bernd J Wintersperger</dc:creator>
<dc:creator>Mukesh G Harisinghani</dc:creator>
<dc:creator>Scott D Flamm</dc:creator>
<dc:creator>Matthias G Friedrich</dc:creator>
<dc:creator>Igor Klem</dc:creator>
<dc:creator>Subha V Raman</dc:creator>
<dc:creator>Daniel Haverstock</dc:creator>
<dc:creator>Zheyu Liu</dc:creator>
<dc:creator>Guenther Brueggenwerth</dc:creator>
<dc:creator>Marta Santiuste</dc:creator>
<dc:creator>Daniel S Berman</dc:creator>
<dc:creator>Dudley J Pennell</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Stress Perfusion Cardiac Magnetic Resonance vs SPECT Imaging for Detection of Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37914512</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.046</dc:identifier>
</item>
<item>
<title>The Ongoing Odyssey of Renal Denervation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1824-1827. doi: 10.1016/j.jacc.2023.09.795.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914511</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.795>10.1016/j.jacc.2023.09.795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914511</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Manish Vinayak</dc:creator>
<dc:creator>Jeffrey W Olin</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Ongoing Odyssey of Renal Denervation</dc:title>
<dc:identifier>pmid:37914511</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.795</dc:identifier>
</item>
<item>
<title>Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37914510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: There was no significant difference between groups in the primary analysis. However, multiple secondary endpoint analyses favored RDN over sham control. (SPYRAL HTN-ON MED Study [Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications]; NCT02439775).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 7;82(19):1809-1823. doi: 10.1016/j.jacc.2023.08.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled hypertension in the absence of antihypertensive medications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This trial assessed the safety and efficacy of RDN in the presence of antihypertensive medications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: SPYRAL HTN-ON MED is a prospective, randomized, sham-controlled, patient- and assessor-blinded trial enrolling patients from 56 clinical centers worldwide. Patients were prescribed 1 to 3 antihypertensive medications. Patients were randomized to radiofrequency RDN or sham control procedure. The primary efficacy endpoint was the baseline-adjusted change in mean 24-hour ambulatory systolic BP at 6 months between groups using a Bayesian trial design and analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The treatment difference in the mean 24-hour ambulatory systolic BP from baseline to 6 months between the RDN group (n = 206; -6.5 ± 10.7 mm Hg) and sham control group (n = 131; -4.5 ± 10.3 mm Hg) was -1.9 mm Hg (95% CI: -4.4 to 0.5 mm Hg; P = 0.12). There was no significant difference between groups in the primary efficacy analysis with a posterior probability of superiority of 0.51 (Bayesian treatment difference: -0.03 mm Hg [95% CI: -2.82 to 2.77 mm Hg]). However, there were changes and increases in medication intensity among sham control patients. RDN was associated with a reduction in office systolic BP compared with sham control at 6 months (adjusted treatment difference: -4.9 mm Hg; P = 0.0015). Night-time BP reductions and win ratio analysis also favored RDN. There was 1 adverse safety event among 253 assessed patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: There was no significant difference between groups in the primary analysis. However, multiple secondary endpoint analyses favored RDN over sham control. (SPYRAL HTN-ON MED Study [Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications]; NCT02439775).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37914510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37914510</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.045>10.1016/j.jacc.2023.08.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37914510</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>David E Kandzari</dc:creator>
<dc:creator>Raymond R Townsend</dc:creator>
<dc:creator>Kazuomi Kario</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Michael A Weber</dc:creator>
<dc:creator>Roland E Schmieder</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Konstantinos Tsioufis</dc:creator>
<dc:creator>Dimitrios Konstantinidis</dc:creator>
<dc:creator>James Choi</dc:creator>
<dc:creator>Cara East</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Debbie L Cohen</dc:creator>
<dc:creator>Taisei Kobayashi</dc:creator>
<dc:creator>Axel Schmid</dc:creator>
<dc:creator>David P Lee</dc:creator>
<dc:creator>Adrian Ma</dc:creator>
<dc:creator>Joachim Weil</dc:creator>
<dc:creator>Tolga Agdirlioglu</dc:creator>
<dc:creator>Markus P Schlaich</dc:creator>
<dc:creator>Sharad Shetty</dc:creator>
<dc:creator>Chandan M Devireddy</dc:creator>
<dc:creator>Janice Lea</dc:creator>
<dc:creator>Jiro Aoki</dc:creator>
<dc:creator>Andrew S P Sharp</dc:creator>
<dc:creator>Richard Anderson</dc:creator>
<dc:creator>Martin Fahy</dc:creator>
<dc:creator>Vanessa DeBruin</dc:creator>
<dc:creator>Sandeep Brar</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>SPYRAL HTN-ON MED Investigators</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications</dc:title>
<dc:identifier>pmid:37914510</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.045</dc:identifier>
</item>
<item>
<title>Magnetic soft robotics to manipulate the extracellular matrix in vitro</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37913767/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>The importance of dynamic mechanical control over the cellular microenvironment has long been appreciated. In a recent issue of Device, Raman and colleagues design a clever yet generalizable tool to achieve this, illustrating magnetic stimulation of an engineered extracellular matrix to induce muscle fiber alignment toward programmed functioning.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 24:S0092-8674(23)01127-3. doi: 10.1016/j.cell.2023.10.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The importance of dynamic mechanical control over the cellular microenvironment has long been appreciated. In a recent issue of Device, Raman and colleagues design a clever yet generalizable tool to achieve this, illustrating magnetic stimulation of an engineered extracellular matrix to induce muscle fiber alignment toward programmed functioning.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37913767/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37913767</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.011>10.1016/j.cell.2023.10.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37913767</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Avinava Roy</dc:creator>
<dc:creator>Claudia Loebel</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Magnetic soft robotics to manipulate the extracellular matrix in vitro</dc:title>
<dc:identifier>pmid:37913767</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.011</dc:identifier>
</item>
<item>
<title>Educational Attainment and Lifetime Risk of Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37910110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Lower education was associated with lifetime CVD risk across adulthood; higher education translated to healthy longevity. Educational policy initiatives may associate with long-term health benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 1:e233990. doi: 10.1001/jamacardio.2023.3990. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Education is a social determinant of health. Quantifying its association with lifetime cardiovascular disease (CVD) risk has public health importance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To calculate lifetime risk estimates of incident CVD and CVD subtypes and estimate years lived with and without CVD by education.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Included community-based cohort studies with adjudicated cardiovascular events used pooled individual-level data from 1985 to 2015 of 6 prospective cohort studies. The study team assessed the association between education and lifetime CVD risk with modified Kaplan-Meier and Cox models accounting for competing risk of noncardiovascular death. The study team estimated years lived with and without CVD by education with the Irwin restricted mean and the utility of adding educational attainment to CVD risk assessment. Participants (baseline 40 to 59 years old and 60 to 79 years old) were without CVD at baseline and had complete education, cardiovascular risk factors, and prospective CVD outcomes data. Data were analyzed from January 2022 to September 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Educational attainment (less than high school, high school completion, some college, or college graduate).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: Cardiovascular events (fatal and nonfatal coronary heart disease, heart failure, and stroke; CVD-related deaths; and total CVD encompassing any of these events).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were 40 998 participants (23 305 female [56.2%]) with a mean (SD) age of 58.1 (9.7) years for males and 58.3 (9.9) years for females. Compared with college graduates, those with less than high school or high school completion had higher lifetime CVD risks. Among middle-aged men, the competing hazard ratios (HRs) for a CVD event were 1.58 (95% CI, 1.38-1.80), 1.30 (95% CI, 1.10-1.46), and 1.16 (95% CI, 1.00-1.34) in those with less than high school, high school, and some college, respectively, compared with those with college completion. Among women, these competing HRs were 1.70 (95% CI, 1.49-1.95), 1.19 (95% CI, 1.05-1.35), and 0.98 (95% CI, 0.83-1.15). Individuals with higher education had longer duration of life prior to incident CVD. Education provided limited contribution toward enhancing CVD risk prediction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Lower education was associated with lifetime CVD risk across adulthood; higher education translated to healthy longevity. Educational policy initiatives may associate with long-term health benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37910110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37910110</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10620672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">PMC10620672</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3990>10.1001/jamacardio.2023.3990</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37910110</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Jared W Magnani</dc:creator>
<dc:creator>Hongyan Ning</dc:creator>
<dc:creator>John T Wilkins</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Educational Attainment and Lifetime Risk of Cardiovascular Disease</dc:title>
<dc:identifier>pmid:37910110</dc:identifier>
<dc:identifier>pmc:PMC10620672</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3990</dc:identifier>
</item>
<item>
<title>Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37910101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231104060732&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION AND RELEVANCE: Results of this cohort study suggest that after PFA for AF, there were no significant sex differences in clinical effectiveness or safety events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 1:e233752. doi: 10.1001/jamacardio.2023.3752. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Previous studies evaluating the association of patient sex with clinical outcomes using conventional thermal ablative modalities for atrial fibrillation (AF) such as radiofrequency or cryoablation are controversial due to mixed results. Pulsed field ablation (PFA) is a novel AF ablation energy modality that has demonstrated preferential myocardial tissue ablation with a unique safety profile.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare sex differences in patients undergoing PFA for AF in the Multinational Survey on the Methods, Efficacy, and Safety on the Postapproval Clinical Use of Pulsed Field Ablation (MANIFEST-PF) registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of MANIFEST-PF registry data, which included consecutive patients undergoing postregulatory approval treatment with PFA to treat AF between March 2021 and May 2022 with a median follow-up of 1 year. MANIFEST-PF is a multinational, retrospectively analyzed, prospectively enrolled patient-level registry including 24 European centers. The study included all consecutive registry patients (age ≥18 years) who underwent first-ever PFA for paroxysmal or persistent AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: PFA was performed on patients with AF. All patients underwent pulmonary vein isolation and additional ablation, which was performed at the discretion of the operator.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary effectiveness outcome was freedom from clinically documented atrial arrhythmia for 30 seconds or longer after a 3-month blanking period. The primary safety outcome was the composite of acute (&lt;7 days postprocedure) and chronic (>;7 days) major adverse events (MAEs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1568 patients (mean [SD] age, 64.5 [11.5] years; 1015 male [64.7%]) with AF who underwent PFA, female patients, as compared with male patients, were older (mean [SD] age, 68 [10] years vs 62 [12] years; P &lt; .001), had more paroxysmal AF (70.2% [388 of 553] vs 62.4% [633 of 1015]; P = .002) but had fewer comorbidities such as coronary disease (9% [38 of 553] vs 15.9% [129 of 1015]; P &lt; .001), heart failure (10.5% [58 of 553] vs 16.6% [168 of 1015]; P = .001), and sleep apnea (4.7% [18 of 553] vs 11.7% [84 of 1015]; P &lt; .001). Pulmonary vein isolation was performed in 99.8% of female (552 of 553) and 98.9% of male (1004 of 1015; P = .90) patients. Additional ablation was performed in 22.4% of female (124 of 553) and 23.1% of male (235 of 1015; P = .79) patients. The 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was similar in male and female patients (79.0%; 95% CI, 76.3%-81.5% vs 76.3%; 95% CI, 72.5%-79.8%; P = .28). There was also no significant difference in acute major AEs between groups (male, 1.5% [16 of 1015] vs female, 2.5% [14 of 553]; P = .19).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: Results of this cohort study suggest that after PFA for AF, there were no significant sex differences in clinical effectiveness or safety events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37910101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">37910101</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10620676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231104060732&v=2.17.9.post6+86293ac">PMC10620676</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3752>10.1001/jamacardio.2023.3752</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37910101</guid>
<pubDate>Wed, 01 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohit K Turagam</dc:creator>
<dc:creator>Petr Neuzil</dc:creator>
<dc:creator>Boris Schmidt</dc:creator>
<dc:creator>Tobias Reichlin</dc:creator>
<dc:creator>Kars Neven</dc:creator>
<dc:creator>Andreas Metzner</dc:creator>
<dc:creator>Jim Hansen</dc:creator>
<dc:creator>Yuri Blaauw</dc:creator>
<dc:creator>Philippe Maury</dc:creator>
<dc:creator>Thomas Arentz</dc:creator>
<dc:creator>Philipp Sommer</dc:creator>
<dc:creator>Ante Anic</dc:creator>
<dc:creator>Frederic Anselme</dc:creator>
<dc:creator>Serge Boveda</dc:creator>
<dc:creator>Tom Deneke</dc:creator>
<dc:creator>Stephan Willems</dc:creator>
<dc:creator>Pepijn van der Voort</dc:creator>
<dc:creator>Roland Tilz</dc:creator>
<dc:creator>Moritoshi Funasako</dc:creator>
<dc:creator>Daniel Scherr</dc:creator>
<dc:creator>Reza Wakili</dc:creator>
<dc:creator>Daniel Steven</dc:creator>
<dc:creator>Josef Kautzner</dc:creator>
<dc:creator>Johan Vijgen</dc:creator>
<dc:creator>Pierre Jais</dc:creator>
<dc:creator>Jan Petru</dc:creator>
<dc:creator>Julian Chun</dc:creator>
<dc:creator>Laurent Roten</dc:creator>
<dc:creator>Anna Füting</dc:creator>
<dc:creator>Marc D Lemoine</dc:creator>
<dc:creator>Martin Ruwald</dc:creator>
<dc:creator>Bart A Mulder</dc:creator>
<dc:creator>Anne Rollin</dc:creator>
<dc:creator>Heiko Lehrmann</dc:creator>
<dc:creator>Thomas Fink</dc:creator>
<dc:creator>Zrinka Jurisic</dc:creator>
<dc:creator>Corentin Chaumont</dc:creator>
<dc:creator>Raquel Adelino</dc:creator>
<dc:creator>Karin Nentwich</dc:creator>
<dc:creator>Melanie Gunawardene</dc:creator>
<dc:creator>Alexandre Ouss</dc:creator>
<dc:creator>Christian-Hendrik Heeger</dc:creator>
<dc:creator>Martin Manninger</dc:creator>
<dc:creator>Jan-Eric Bohnen</dc:creator>
<dc:creator>Arian Sultan</dc:creator>
<dc:creator>Petr Peichl</dc:creator>
<dc:creator>Pieter Koopman</dc:creator>
<dc:creator>Nicolas Derval</dc:creator>
<dc:creator>Thomas Kueffer</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:date>2023-11-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37910101</dc:identifier>
<dc:identifier>pmc:PMC10620676</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3752</dc:identifier>
</item>





























</channel>
</rss>